HSBC reiterated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Tuesday, ThisIsMoney.Co.Uk reports.
Other research analysts also recently issued reports about the stock. Shore Capital downgraded shares of GlaxoSmithKline to a hold rating in a research report on Friday, January 18th. Jefferies Financial Group restated a buy rating and set a GBX 1,750 ($22.87) price objective on shares of GlaxoSmithKline in a research report on Tuesday, April 23rd. Liberum Capital restated a hold rating on shares of GlaxoSmithKline in a research report on Friday, March 8th. Barclays restated an equal weight rating on shares of GlaxoSmithKline in a research report on Tuesday, January 15th. Finally, Deutsche Bank restated a hold rating and set a GBX 1,520 ($19.86) price objective on shares of GlaxoSmithKline in a research report on Friday, April 5th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of GBX 1,526.14 ($19.94).
LON GSK opened at GBX 1,527.60 ($19.96) on Tuesday. The company has a debt-to-equity ratio of 942.07, a current ratio of 0.72 and a quick ratio of 0.45. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,648.80 ($21.54). The company has a market capitalization of $75.46 billion and a PE ratio of 19.46.
In related news, insider Emma Walmsley sold 66,159 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of GBX 1,585 ($20.71), for a total value of £1,048,620.15 ($1,370,207.96). Also, insider Manvinder Singh Banga acquired 458 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, May 1st. The stock was acquired at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Story: What is a capital gain?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.